Get In Touch
Have any questions or comments about the content you see on this page?
April 24, 2023
For more than 20 years, Alnylam has been leading the way, advancing RNAi therapeutics as a whole new class of innovative medicines and this past year was no different. In fact, 2022 proved to be a banner year for Alnylam marked by significant milestones and steady progress on our journey toward achieving our 5-year vision, Alnylam P5x25.
I invite you to explore all of Alnylam’s achievements and advancements in our 2022 Annual Report, and I’m proud to share some key highlights here:
Continued Commercial Successes – we achieved $894 million in global net product revenue from our wholly owned marketed medicines – ONPATTRO(patisiran), GIVLAARI (givosiran) and OXLUMO (lumasiran). This represents 35% year-over-year growth, a total of over 3,800 patients who are now receiving our approved RNAi therapies and reflects robust patient demand for our innovative and transformative products.
Regulatory Milestones – we continue to make our wholly owned medicines available to patients around the world and in 2022, we received regulatory approval of AMVUTTRA, the first and only U.S. FDA-approved treatment demonstrating reversal in neuropathy impairment and saw the approval of our first supplemental New Drug Application (sNDA) for label expansion of OXLUMO.
Progress in R&D/Our Pipeline – we continue to progress a robust, high-yielding clinical pipeline with a diversity of opportunity across nearly a dozen programs at all stages of development.
RNAi Therapeutic Platform Enhancements – Important platform advancements enabled the development of new conjugate delivery technology, C16 enabling us to target new extrahepatic tissues, including the eye, the lung, and the central nervous system. Our Phase 1 ALN-APP program in early onset Alzheimer's disease and cerebral amyloid angiopathy is our first clinical program to utilize C16.
Supporting Patients – Our Patient Access Philosophy is built on the notion that for our medicines to have the broadest possible impact, we must work hard to ensure that everyone who may benefit from them are able to access to them. Our therapies are now available in more than 60 markets in North America, South America, Europe, Asia-Pacific, and the Middle East, either directly from Alnylam or through distributors.
Corporate Responsibility – Our approach to corporate responsibility stems from our core values and emphasizes our commitment to tackling unprecedented and complex challenges, taking courageous action, and using our business as a force for good. We’re proud to be recognized for our efforts by Newsweek as one of America's Most Responsible Companies.
An Employer of Choice – In 2022, we increased our workforce by more than 20% and now have over 2,000 employees in 23 countries. Our award-winning culture was recognized more than a dozen times including #1 Best Workplace for Innovators by Fast Company, #2 on Science Magazine’s Top BioPharma Employers list, and for the second year in a row we were voted the #1 Largest Employer in The Boston Globe Top Places to Work list—our eighth consecutive year making the list.
In closing, I want to thank all my Alnylam colleagues who continue to drive us forward in relentless pursuit of scientific and commercial advancement, innovation, and excellence. We’re confident in the power of RNAi for human health and its potential to fuel the discovery of new therapeutics for patients around the world for decades to come. I look forward to our next chapter in the RNAi Revolution and reporting out on our 2023 accomplishments again this time next year.
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.Proceed to Site